Amarin Corp Plcuk (AMRN) EBITDA Margin (2013 - 2026)

Amarin Corp Plcuk (AMRN) posted quarterly EBITDA Margin of 25.11% for Q1 2026, up 1476.0% YoY from 1.59% in Q1 2025, and down 135.48% sequentially from 70.77% in Q4 2025.

Amarin Corp Plcuk (AMRN) EBITDA Margin (2013 - 2026) Analysis & Trends

Amarin Corp Plcuk has disclosed EBITDA Margin across 14 years of filings, most recently posting 25.11% for Q1 2026.

  • In Q1 2026, EBITDA Margin rose 1476.0% year-over-year to 25.11%; the TTM figure through Mar 2026 stood at 1.66% (up 884.0% YoY), while the FY2025 annual figure was 4.22%, up 422.0% from the prior year.
  • EBITDA Margin declined to 25.11% in Q1 2026, from 70.77% in the prior quarter.
  • Over the last five years, EBITDA Margin for AMRN reached as high as 70.77% in Q4 2025 and fell as low as 66.53% in Q2 2022.
  • The 5-year median for EBITDA Margin is 22.35% (2025), against an average of 12.95%.
  • Annual changes were most pronounced in 2022 — EBITDA Margin sank 7221 bps — and 2023, when it jumped 7665 bps.
  • A 5-year view of EBITDA Margin shows it stood at 10.62% in 2022, then surged by 722 bps to 66.03% in 2023, then slumped by 51 bps to 32.06% in 2024, then jumped by 121 bps to 70.77% in 2025, then tumbled by 135 bps to 25.11% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods registered 25.11%, 70.77%, and 22.35% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 47.98%
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 26.44%
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 26.60%
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 18.85%
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -47.46%
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 30.94%
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 37.16%
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -286.83%
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Amarin Corp Plcuk 5.17 Bn 5.00 Bn 17.77 Mn -25.11%

Historic Data

Download Data
DateValue
Mar 31, 2026 -25.11%
Dec 31, 2025 70.77%
Sep 30, 2025 -22.35%
Jun 30, 2025 -21.98%
Mar 31, 2025 -39.88%
Dec 31, 2024 32.06%
Sep 30, 2024 -59.50%
Jun 30, 2024 -0.78%
Mar 31, 2024 -24.03%
Dec 31, 2023 66.03%
Sep 30, 2023 -32.47%
Jun 30, 2023 -29.89%
Mar 31, 2023 -20.17%
Dec 31, 2022 -10.62%
Sep 30, 2022 -5.72%
Jun 30, 2022 -66.53%
Mar 31, 2022 -29.91%
Dec 31, 2021 5.85%
Sep 30, 2021 -9.20%
Jun 30, 2021 5.68%